Proteins differently synthesized between HT29 and SW480 cells as determined by 2D-PAGE fluorescence.

<p>Checkmarks indicate correlation with shotgun analysis (SG).</p><p>Proteins differently synthesized between HT29 and SW480 cells as determined by 2D-PAGE fluorescence.</p

Demographic and baseline characteristics of the study population.

Data are depicted as absolute numbers or mean±standard deviation. Abbreviations: APACHE, acute physiology and chronic health evaluation; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; PRBCs, packed red blood cells.</p

Protein regulation in SW480 and HT29 after treatment with 5 µM Ciglitazone as determined by 2D-PAGE autoradiography scans.

<p>Proteins upregulated more than three-fold with statistical significance (p<0.05) are indicated by bold letters. Proteins involved in chaperoning functions are displayed in italic font.</p><p>Protein regulation in SW480 and HT29 after treatment with 5 µM Ciglitazone as determined by 2D-PAGE autoradiography scans.</p

Changes of hemodynamic and laboratory parameters at 15 and 60 min following start of transfusion.

Data are depicted as mean±standard deviation. P-values (Welch’s t-Test) indicate differences among patients receiving fresh and standard-issue PRBCs. Statistically significant data are printed bold. Abbreviations: Δ15, change in parameter during transfusion; Δ60, change in parameter within the first 60 minutes after starting transfusion; CI, cardiac index; Hb, hemoglobin; MIF, macrophage migration inhibitory factor; PAP, pulmonary arterial pressure; PRBCs, packed red blood cells; PVRI, pulmonary vascular resistance index; SDC, syndecan-1; SVRI, systemic vascular resistance index; MAP, mean arterial pressure; CI, cardiac index.</p

Changes in pulmonary arterial pressure and pulmonary vascular resistance index at 15 minutes after initiation of transfusion.

Change in (A) pulmonary arterial pressure (Δ PAP) and (B) pulmonary vascular resistance index (Δ PRVI) at 15 minutes after initiation of transfusion in patients receiving fresh packed red blood cells (fresh PRBCs, white bars) or standard-issue packed red blood cells (standard-issue PRBCs, grey bars). Black dots represent respective changes in individual patients. P-values indicate differences among patients receiving fresh PRBCs and standard-issue PRBCs.</p

Study participation flow diagram.

Abbreviations: PAC, pulmonary artery catheter; Hb, hemoglobin; ICU, intensive care unit; SAE, serious adverse event; PRBCs, packed red blood cells.</p

Hemodynamic parameters at baseline, and within 15 minutes and 60 minutes after transfusion.

P-values (Welch’s t-Test) indicate differences versus baseline within each group. Abbreviations: BL, baseline; CI, cardiac index; MAP, mean arterial pressure; PAP, pulmonary arterial pressure; PRBC, packed red blood cells; PVRI, pulmonary vascular resistance index; SVRI, systemic vascular resistance index.</p

Protein synthesis in untreated colorectal adenocarcinoma cell lines.

<p>Representative 2D-PAGE gels of untreated (A) HT29 and (B) SW480 cells. Proteins synthesized to a greater extent in HT29 cells are indicated by hexagons, those in SW480 cells by circles. Accession numbers of proteins listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114158#pone-0114158-t001" target="_blank">Table 1</a> are annotated according to the UniProtKB/Swiss-Prot database. (C) Total proteins identified by shotgun analysis in HT29 and SW480 cells.</p

Cell responsiveness of colorectal adenocarcinoma cell lines after treatment with Ciglitazone.

<p>2D-PAGE gels were performed in (A) HT29 and (B) SW480 cells after treatment with 5 µM Ciglitazone. (1) Fluorescence scans of untreated cells, (2) fluorescence scans of cells treated with Ciglitazone, (3) autoradiography scans of untreated cells, (4) autoradiography scans of cells treated with Ciglitazone. Cell cycle distribution of (C) HT29 and (D) SW480 cells treated with increasing concentrations of Ciglitazone.</p

Cell viability and mitochondrial membrane potential after treatment with thiazolidinediones.

<p>Cell viability was assessed by neutral red uptake in SW480 and HT29 cells treated with increasing concentrations of (A) Ciglitazone or (B) Troglitazone for 6 and 24 hours. *p<0.05, values of HT29 cells differ from those of SW480 cells. Mitochondrial membrane potential (Δψ_m) was assessed by JC-1 FACS analysis in (C) HT29 and (D) SW480 cells treated with increasing concentrations of Ciglitazone for 24 and 48 hours. *p<0.05, values at 48 hours differ from those at 24 hours. #p<0.05, values at indicated concentrations differ from baseline.</p